Dammmm...., page-31

Some opinions

Morgans

http://www.morgans.com.au/Blog/2014/October/Alchemia-misses-primary-endpoint.aspx

"Alchemia Limited (ACL) has announced that it has missed primary endpoint for its pivotal Phase III trial for the treatment of metastatic colorectal cancer.
This is a major disappointment and the share price will come under significant selling pressure today. We recommend clients urgently review their holdings with the increased risk of ACL now being unsuitable for many investor's portfolios.
We reduce our share price target to A$0.19 (previously A$0.88)."


Criterion

http://www.theaustralian.com.au/bus...-the-other-gains/story-e6frg9lo-1227104047167

A snip

"As for Alchemia holders, the question is how much value lies in ongoing royalties from Alchemia’s blood-thinning drug.
This assumes the cancer drug program indeed is dead, buried and cremated.
We suspect the answer is more than what Alchemia’s current market cap of $34 million implies, especially as Alchemia has $8.9m cash with a $6.5m R&D refund due next month. Spec buy."



Sad after 7 years holding I've bailed